ANL ANL
Company Profile ↓Company Overview
ANL (ANL) is a publicly traded company listed on with a market capitalization of $2.30B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Net profit has compounded at 13.2% per year over the last five years.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR 13.2%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | 13.19% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +743.23% |
| 6 Months: | +39.04% |
| 3 Months: | -12.46% |
| 1 Month: | +21.36% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.35 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 13.2% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 5.00M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 67.27M | 72.55M | 52.93M | 40.70M |
| Operating Income | - | -67.27M | -72.55M | -52.93M | -35.70M |
| EBITDA | - | -56.32M | -106.22M | -48.05M | -32.63M |
| Interest Expense | - | 433.00K | 791.00K | 1.94M | 1.49M |
| Pretax Income | - | -58.79M | -109.23M | -51.87M | -35.53M |
| Tax Provision | - | 0 | 0 | 0 | 0 |
| Net Income | - | -58.79M | -109.23M | -51.87M | -35.53M |
| Diluted EPS | - | -1.59 | -7.56 | -1.62 | -1.11 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 72.59M | 130.19M | 71.27M | 34.43M |
| Current Assets | - | 66.30M | 101.19M | 64.06M | 26.89M |
| Cash & Equivalents | - | 42.76M | 91.49M | 60.90M | 8.06M |
| Inventory | - | - | - | - | - |
| Receivables | - | 346.00K | 359.00K | 1.17M | 1.39M |
| Total Liabilities | - | 313.89M | 55.14M | 45.78M | 42.76M |
| Current Liabilities | - | 312.65M | 49.67M | 45.36M | 41.63M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 6.54M | 31.55M | 27.23M | 26.38M |
| Total Equity | - | -241.29M | 75.05M | 25.48M | -8.32M |
| Shares Outstanding | - | 110.70M | 110.70M | 110.70M | 176.22M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -43.22M | -56.65M | -51.82M | -33.45M |
| Investing Cash Flow | - | 28.38M | -10.95M | 28.07M | -15.58M |
| Financing Cash Flow | - | -6.78M | 116.24M | -6.58M | -3.81M |
| Capital Expenditure | - | -1.27M | -200.00K | -170.00K | -187.00K |
| Free Cash Flow | - | -44.49M | -56.85M | -51.99M | -33.64M |
| Net Change in Cash | - | -21.63M | 48.63M | -30.33M | -52.84M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -714.0% |
| Net Margin % | - | - | - | - | -710.6% |
| ROE % | - | 24.4% | -145.5% | -203.5% | 426.9% |
| ROCE % | - | 28.0% | -90.1% | -204.3% | 496.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ANL
Adlai Nortye Announces First-in-Class AN4035 Cleared for Phase I Clinical Development as First Pan-RAS(ON) ADC to Enter the Clinic - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxNd2NwV1lLc3A5Z3ZMWTNJenV2MkdNY1dTaGEwbnVQZUFVNlcxMEVUSDBsY1ZPNXVLSXZOa29DakFKSUtqUmMzQnU2N0M1aWZhZXVwUE4xOXdsWGZYUmlpaF8tOFd3b0hGOW1DWGFrNU1BbjNCMnZkTWFvMmM5TUdhLUpFQzdMLWRMNjVaV1…
Adlai Nortye Ltd. Revenue Breakdown – NASDAQ:ANL - TradingView
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE00eHBHSERCVHk0SndOamg1MWwtWUF2eEhENmR4bkpoU1cxbEF6dFdBR3BXVXE1YjFTd2NhYVJxczV1clpsaXhrcS1FV25WMVdtMHQyUXQ4MlpVUzBVbzc1d0hsV2dILUhfOGFxNWt2SmRmTmpYZ1E?oc=5" target="_blank">Adlai No…
Adlai Nortye (NASDAQ: ANL) secures ethics nod for AN4035 Phase I cancer trial - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOM3dSRTY3Nkp6NktxQ3ZsSFgwd05NTzdERi03RjVhdHd6Y2xoZDJsVEVITHFzbDk2UFFtNmVoX1JKODZjbHRBNW53UUFGT0kySElaZ1Q5NEd5VnVXWWxwSjJUWGlUYkpWbl9hX0dWR0lkcmYzOHdlODBKX0xzQkVVUHl6Tjdpa2Q4MXI4cF…
Adlai Nortye: AN9025 Still Needs Human Validation (NASDAQ:ANL) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNNUIweHNiV1lVSnNxU21wenNtOTZOR2Z1UFVTN1dKSkxaVXNkenRsLTdMTVltMFduTVNISGVJUXRNaDgxaF9HUUR6eWtSSTQybWdEb25iYUZWaXptYk9RNk1JVXpsZ296cUFsRzRrcXRpSGpoMVJEOU9xS2UwVTlZVy1kQVFsR2JpYlhNdm…
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNLW9zWEpfNmRKb0R1X1RzTkJFYnBWNVdSVG5ENGZhcmNyZlJNbUhQNEZZV0V6MVhRSWtLeHJEVVZqZThBeEZjN3RDV1dlOFJIT3lsOXBVTnRVeThtRFJHUl9qTHNQR0RsTEJ4Y1dxYWREQVdRUGhscmd4eHdSMG9naEpNNXZOXzdsZ1RnYX…
Adlai Nortye Ltd.'s (NASDAQ:ANL) market cap surged US$65m last week, retail investors who have a lot riding on the company were rewarded - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxOc1hlTU1TNktoeTJfQzZFNklxTDFKbDJydHFCRDFpczBKckFEY0NaeXNVUF8tdHV5TldtOWVyX0xTY1RyWDZSWHo4a0hId09MazhtYzA1ZlI4MjR2MDZEZ2NHQ3IyeWszLUxHNFpXNDY2TUJWemZfWE85bFJpbEs0NjlpOW1lQVZQZjhLdH…
ANL — Frequently Asked Questions
What is the current share price of ANL?
As of 2026-08-05 17:25 PDT, ANL trades at $13.07 on NASDAQ/NYSE. Its 52-week range is $0.88 to $16.60.
What is the market capitalisation of ANL?
ANL has a market capitalisation of $2.30B on NASDAQ/NYSE.
What is the P/E ratio of ANL?
ANL trades at a trailing price-to-earnings (P/E) ratio of -11.77. Its price-to-book (P/B) ratio is -276.91.
Is ANL a good stock to buy?
This page provides a data-driven analysis of ANL, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.